Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BHV-7000 | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BHV-7000 | Drug | BHV-7000 75 mg taken once daily for 6 weeks |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Montgomery- Ã…sberg Depression Rating Scale (MADRS) total score from baseline to week 6 | The MADRS is a clinician- rated scale to assess depressive symptoms which consists of 10 items. Each item is scored on 7-point scale (0 [absence of symptoms] to 6 [severe]). A higher score represents a higher severity of the level of depression (total scores range from 0 to 60). | Baseline to Week 6 |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Clinical Global Clinical Impression - Severity Scale (CGI-S) total score | The CGI-S is a clinician-rated scale to assess disease severity. The scale is scored on 8-point scale (0 [not assessed] to 7 [severe]). A higher score represents a higher severity illness. | Baseline to Week 6 |
| Change in Snaith-Hamilton Pleasure Scale (SHAPS) total score from baseline to week 6 |
Not provided
Key Inclusion Criteria:
Key Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| IMA Clinical Research | Phoenix | Arizona | 85012 | United States | ||
| Pillar Clinical Research, LLC |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Matching placebo taken once daily for 6 weeks |
|
The SHAPS is a subject self- administered scale to measure hedonic capacity which consists of 14 items (total scores range from 0 to 14). Each item has a set of 4 possible responses (Strongly or Definitely Agree, Agree, Disagree and Strongly Disagree). A total score is derived by summing the responses to each item. A higher score represents a higher level of anhedonia. |
| Baseline to Week 6 |
| Change in Montgomery- Ã…sberg Depression Rating Scale (MADRS) total score from baseline to week 1 | The MADRS is a clinician- rated scale to assess depressive symptoms which consists of 10 items. Each item is scored on 7-point scale (0 [absence of symptoms] to 6 [severe]). A higher score represents a higher severity of the level of depression (total scores range from 0 to 60). | Baseline to Week 1 |
| Change in Snaith-Hamilton Pleasure Scale (SHAPS) total score from baseline to week 1 | The SHAPS is a subject self- administered scale to measure hedonic capacity which consists of 14 items (total scores range from 0 to 14). Each item has a set of 4 possible responses (Strongly or Definitely Agree, Agree, Disagree and Strongly Disagree). A total score is derived by summing the responses to each item. A higher score represents a higher level of anhedonia. | Baseline to Week 1 |
| Change in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q- LES-Q-SF) total score | The Q-LES-Q-SF is a participant self-administered scale to assess the degree of enjoyment and satisfaction experienced in various areas of daily functioning. The form consists of 16 items. Each item is scored on 5-point scale. A higher score represents a higher level of satisfaction and enjoyment (total scores range from 14 to 70). | Baseline to Week 6 |
| Number of Participants With Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and AEs judged to be related to study medication | Safety and tolerability of BHV-7000 as assessed by frequency of unique subjects with SAEs; AEs leading to discontinuation; AEs judged to be related to study medication | Screening through Week 8 |
| Number of Participants With Clinically Significant Laboratory Abnormalities | To assess the safety and tolerability of BHV-7000. This objective will be measured by assessing the number of unique subjects with grade 3 or 4 laboratory abnormalities. | Screening through Week 8 |
| Number of Participants With Vital Sign Abnormalities | Screening through Week 8 |
| Number of Participants With Electrocardiogram (ECG) Abnormalities specific to QTc elevation | Screening through Week 8 |
| Little Rock |
| Arkansas |
| 72204 |
| United States |
| WIRG | Little Rock | Arkansas | 72211 | United States |
| WRN | Rogers | Arkansas | 72758 | United States |
| Advanced Research Center, Inc. | Anaheim | California | 92805 | United States |
| CIT LA | Bellflower | California | 90706 | United States |
| IPMG | Chino | California | 91710 | United States |
| WR-PRI Encino | Encino | California | 91316 | United States |
| Collaborative Neuroscience Research, LLC (CenExel - CNS) | Garden Grove | California | 92845 | United States |
| CalNeuro Research Group | Los Angeles | California | 90025 | United States |
| Excell Research, Inc. | Oceanside | California | 92056 | United States |
| NRC Research Institute | Orange | California | 92868 | United States |
| Anderson Clinical Research | Redlands | California | 92374 | United States |
| CIT IE | Riverside | California | 92506 | United States |
| Lumos Clinical Research Center | San Jose | California | 95124 | United States |
| Stanford | Stanford | California | 94305 | United States |
| Cenexel CNS | Torrance | California | 90504 | United States |
| Pacific Clinical Research Management Group | Upland | California | 91786 | United States |
| Sunwise Clinical Research | Walnut Creek | California | 94596 | United States |
| MCB Clinical Research Centers | Colorado Springs | Colorado | 80910 | United States |
| UConn Health | Farmington | Connecticut | 06030 | United States |
| Optum Behavioral Care of Connecticut, PC dba Comprehensive Psychiatric Care of Connecticut | Norwich | Connecticut | 06360 | United States |
| Clinical Neuroscience Solutions, Inc | Jacksonville | Florida | 32256 | United States |
| Floridian Neuroscience Institute | Miami Lakes | Florida | 33016 | United States |
| Clinical Neuroscience Solutions, Inc. | Orlando | Florida | 32801 | United States |
| K2 Medical Research | Tampa | Florida | 33607 | United States |
| Neuroscience Research Institute | West Palm Beach | Florida | 33407 | United States |
| CenExel iResearch, LLC | Decatur | Georgia | 30030 | United States |
| CenExel iResearch, LLC | Savannah | Georgia | 31405 | United States |
| Uptown Research Institute | Chicago | Illinois | 60640 | United States |
| Revive Research Institute, Inc. | Elgin | Illinois | 60123 | United States |
| Collective Medical Research | Overland Park | Kansas | 66210 | United States |
| Delricht Research | New Orleans | Louisiana | 70115 | United States |
| Headlands Pharmasite | Baltimore | Maryland | 21208 | United States |
| CBH Health | Gaithersburg | Maryland | 20877 | United States |
| Copley Clinical | Boston | Massachusetts | 02116 | United States |
| Boston Clinical Trials | Boston | Massachusetts | 02131 | United States |
| Adams Clinical | Watertown | Massachusetts | 02472 | United States |
| Precise Clinical Research | Flowood | Mississippi | 39232 | United States |
| Arch Clinical Trials | St Louis | Missouri | 63141 | United States |
| IMA Clinical Research | Las Vegas | Nevada | 89102 | United States |
| Bio Behavioral Health | Toms River | New Jersey | 08755 | United States |
| SPRI Clinical Trials, LLC | Brooklyn | New York | 11235 | United States |
| Neurobehavioral Research, Inc | Cedarhurst | New York | 11516 | United States |
| Bioscience Research LLC | Mount Kisco | New York | 10549 | United States |
| Berman Clinical | New York | New York | 10029 | United States |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | United States |
| The Medical Research Network, LLC | New York | New York | 10128 | United States |
| RBA | Staten Island | New York | 10329 | United States |
| Lehigh Center for Clinical Research | Allentown | Pennsylvania | 18104 | United States |
| Suburban Research Associates | Media | Pennsylvania | 19063 | United States |
| Scranton Medical Institute | Moosic | Pennsylvania | 18509 | United States |
| Coastal Carolina Research Center | North Charleston | South Carolina | 29405 | United States |
| Donald J. Garcia, MD, PA dba Austin Clinical Trial Partners | Austin | Texas | 78737 | United States |
| FutureSearch Trials of Dallas | Dallas | Texas | 75234 | United States |
| Relaro Medical Trials, LLC | Dallas | Texas | 75243 | United States |
| InSite Clinical Research, LLC | DeSoto | Texas | 75115 | United States |
| Red Oak Psychiatry Associates, PA | Houston | Texas | 77373 | United States |
| Aim Trials | Plano | Texas | 75093 | United States |
| Grayline Research Center | Wichita Falls | Texas | 76309 | United States |
| Alpine Reseach Organization | Clinton | Utah | 84015 | United States |
| Northwest Clinical Research Center | Bellevue | Washington | 98007 | United States |
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D003863 | Depression |
| D003244 | Consciousness Disorders |
| D003866 | Depressive Disorder |
| ID | Term |
|---|---|
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D019965 | Neurocognitive Disorders |
Not provided
Not provided